Structural Polymorphism of Sorafenib Tosylate as a Key Factor in Its Solubility Differentiation.

ABSTRACT: The presence of active pharmaceutical ingredients (APIs) in the forms of different polymorphic states can induce differences in their physicochemical properties. In the case of poorly soluble APIs, like the oncological drug sorafenib tosylate, small variations in solubility may result in large bioavailability differences. The control of its therapeutic dose is crucial from the effective pharmacotherapy point of view and the reduction of side effects. Therefore, this study aimed to assess the influence of sorafenib tosylate polymorphic forms on its solubility and, consequently, permeability, based on passive diffusion through membranes simulating the gastrointestinal tract (GIT) conditions. In the first part of the work, two crystalline forms of sorafenib tosylate were identified using the

SUBMITTER: Wiergowska G 

PROVIDER: S-EPMC8002161 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature